Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Penicillamine
Drug ID BADD_D01709
Description Penicillamine is a pharmaceutical of the chelator class. The pharmaceutical form is D-penicillamine, as L-penicillamine is toxic (it inhibits the action of pyridoxine). It is an α-amino acid metabolite of penicillin, although it has no antibiotic properties.
Indications and Usage For treatment of Wilson's disease, cystinuria and active rheumatoid arthritis.
Marketing Status Prescription; Discontinued
ATC Code M01CC01
DrugBank ID DB00859
KEGG ID D00496
MeSH ID D010396
PubChem ID 5852
TTD Drug ID D08HZC
NDC Product Code 0591-4171; 68022-7041; 76003-0870; 0395-8148; 51991-974; 25010-705; 49884-146; 0037-4401; 42973-230; 71052-491; 51552-1096; 43598-634; 76339-159; 43975-309; 60505-4696; 59285-014; 70748-153; 62207-013; 71205-916; 68475-201; 70010-907; 59651-245; 62559-970; 0254-2000; 38779-0244; 72640-012; 70159-004; 68682-020
Synonyms Penicillamine | Mercaptovaline | D-Penicillamine | D Penicillamine | Dimethylcysteine | beta,beta-Dimethylcysteine | beta,beta Dimethylcysteine | D-3-Mercaptovaline | D 3 Mercaptovaline | Metalcaptase | Cuprimine | Copper Penicillaminate | Penicillaminate, Copper | Cuprenil
Chemical Information
Molecular Formula C5H11NO2S
CAS Registry Number 771431-20-0
SMILES CC(C)(C(C(=O)O)N)S
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Congenital, familial and genetic disordersElastinP15502Not Available3063003; 6216862; 7068961; 7282106; 3319968; 6939876; 7362666; 16144289; 6439866; 1536698; 8912569; 6658398; 4018948; 10352832; 3459889; 3213269; 3707633; 2082056; 8045756
Congenital, familial and genetic disordersCollagen alpha-1(I) chainP02452Not Available3063003; 6216862; 7068961; 7282106; 3319968; 6939876; 7362666; 16144289; 6439866; 1536698; 8912569; 6658398; 4018948; 10352832; 3459889; 3213269; 3707633; 2082056; 8045756
Cutis laxaCollagen alpha-1(I) chainP02452Not Available3063003; 6216862; 7068961; 7282106; 3319968; 6939876; 7362666; 16144289; 6439866; 1536698; 8912569; 6658398; 4018948; 10352832; 3459889; 3213269; 3707633; 2082056; 8045756
Cutis laxaElastinP15502Not Available3063003; 6216862; 7068961; 7282106; 3319968; 6939876; 7362666; 16144289; 6439866; 1536698; 8912569; 6658398; 4018948; 10352832; 3459889; 3213269; 3707633; 2082056; 8045756
DermatomyositisMHC class I antigenO19755Not Available1411195; 3501473; 8403583; 3134689; 94219; 6658398; 6305039; 3492852; 3738397; 6334465; 3707633; 3929421; 1604135; 4018948; 3704516; 3437418; 843119; 7697959
DermatomyositisMHC class I antigen HLA-B18O77967Not Available1411195; 3501473; 8403583; 3134689; 94219; 6658398; 6305039; 3492852; 3738397; 6334465; 3707633; 3929421; 1604135; 4018948; 3704516; 3437418; 843119; 7697959
DermatomyositisHLA-DR4 proteinO77963Not Available1411195; 3501473; 8403583; 3134689; 94219; 6658398; 6305039; 3492852; 3738397; 6334465; 3707633; 3929421; 1604135; 4018948; 3704516; 3437418; 843119; 7697959
Elastosis perforansCollagen alpha-1(I) chainP02452Not Available3063003; 6216862; 7068961; 7282106; 3319968; 6939876; 7362666; 16144289; 6439866; 1536698; 8912569; 6658398; 4018948; 10352832; 3459889; 3213269; 3707633; 2082056; 8045756
Elastosis perforansElastinP15502Not Available3063003; 6216862; 7068961; 7282106; 3319968; 6939876; 7362666; 16144289; 6439866; 1536698; 8912569; 6658398; 4018948; 10352832; 3459889; 3213269; 3707633; 2082056; 8045756
Impaired healingElastinP15502Not Available3063003; 6216862; 7068961; 7282106; 3319968; 6939876; 7362666; 16144289; 6439866; 1536698; 8912569; 6658398; 4018948; 10352832; 3459889; 3213269; 3707633; 2082056; 8045756
Impaired healingCollagen alpha-1(I) chainP02452Not Available3063003; 6216862; 7068961; 7282106; 3319968; 6939876; 7362666; 16144289; 6439866; 1536698; 8912569; 6658398; 4018948; 10352832; 3459889; 3213269; 3707633; 2082056; 8045756
PolymyositisHLA class II histocompatibility antigen, DRB1 beta chainP01911Not Available4018948; 3133153; 6605118; 3415364
Skin fragilityCollagen alpha-1(I) chainP02452Not Available3063003; 6216862; 7068961; 7282106; 3319968; 6939876; 7362666; 16144289; 6439866; 1536698; 8912569; 6658398; 4018948; 10352832; 3459889; 3213269; 3707633; 2082056; 8045756
Skin fragilityElastinP15502Not Available3063003; 6216862; 7068961; 7282106; 3319968; 6939876; 7362666; 16144289; 6439866; 1536698; 8912569; 6658398; 4018948; 10352832; 3459889; 3213269; 3707633; 2082056; 8045756
Skin toxicityHLA-DRB3*02.01 class II antigen beta III (DRw6b)Q6LBW5Not Available3133153; 6770269; 3157529; 6439866; 3133152; 6376799; 3437418; 8151585; 3492038; 6959574; 6234391; 6402993; 3482988; 2570550; 6420562; 3487119; 8846545
Toxicity to various agentsHLA class II histocompatibility antigen, DR beta 5 chainQ30154Not AvailableNot Available
Toxicity to various agentsHLA class I histocompatibility antigen, B alpha chainP01889Not AvailableNot Available
Toxicity to various agentsHLA-DR3Q29887Not AvailableNot Available
Toxicity to various agentsHLA class II histocompatibility antigen, DRB1 beta chainP01911Not Available4018948; 3133153; 6605118; 3415364
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Stomatitis07.05.06.005--
Synovitis15.04.02.001--Not Available
Systemic lupus erythematosus23.03.02.006; 15.06.02.003; 10.04.03.004--Not Available
Thrombocytopenia01.08.01.002--Not Available
Thrombocytosis01.08.02.001--Not Available
Thrombophlebitis24.01.02.001--Not Available
Thrombotic thrombocytopenic purpura24.07.06.014; 23.06.01.011; 01.08.01.005--
Thyroiditis05.02.04.001--Not Available
Tinnitus04.04.01.002; 17.04.07.004--
Toxic epidermal necrolysis23.03.01.008; 12.03.01.015; 11.07.01.006; 10.01.01.006--
Urethral disorder20.07.01.002--Not Available
Urinary tract disorder20.08.01.001--Not Available
Urticaria10.01.06.001; 23.04.02.001--
Vasculitis24.05.02.001; 10.02.02.006--
Visual impairment06.02.06.008--Not Available
Vitamin B6 deficiency14.12.02.005--Not Available
Vomiting07.01.07.003--
Yellow nail syndrome23.02.05.009; 22.03.02.001--Not Available
Red blood cell sedimentation rate increased13.01.03.001--Not Available
Lupus-like syndrome10.04.03.003; 23.03.02.004; 15.06.02.004--Not Available
Lymphatic disorder01.09.01.003--Not Available
Pruritus generalised23.03.12.003--Not Available
Protein urine present13.13.02.006--Not Available
Musculoskeletal discomfort15.03.04.001--Not Available
Haemorrhage24.07.01.002--Not Available
Angiopathy24.03.02.007--Not Available
Blood alkaline phosphatase increased13.04.02.004--
Mental disorder19.07.01.002--Not Available
Decreased appetite14.03.01.005; 08.01.09.028--
Blood disorder01.05.01.0040.000360%Not Available
The 4th Page    First    Pre   4 5    Next   Last    Total 5 Pages